Investors Capital Advisory Services’s Teva Pharmaceuticals TEVA Stock Holding History

Investors Capital Advisory Services’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$463K	Buy	9,224 +213	+2%	+$11.3K	0.09%	299
2016 Q1	$482K	Buy	9,011 +377	+4%	+$22.1K	0.1%	277
2015 Q4	$566K	Buy	8,634 +1,069	+14%	+$66.1K	0.11%	257
2015 Q3	$427K	Sell	7,565 -1,989	-21%	-$129K	0.09%	326
2015 Q2	$564K	Sell	9,554 -55	-0.6%	-$3.39K	0.1%	283
2015 Q1	$598K	Sell	9,609 -119	-1%	-$6.92K	0.11%	253
2014 Q4	$559K	Sell	9,728 -160	-2%	-$8.91K	0.11%	272
2014 Q3	$531K	Sell	9,888 -293	-3%	-$15.5K	0.1%	281
2014 Q2	$533K	Sell	10,181 -531	-5%	-$27.1K	0.09%	333
2014 Q1	$566K	Sell	10,712 -185	-2%	-$8.55K	0.12%	249
2013 Q4	$436K	Buy	10,897 +5	+0%	+$197	0.1%	290
2013 Q3	$411K	Sell	10,892 -444	-4%	-$17.3K	0.11%	284
2013 Q2	$444K	Buy	+11,336	New	+$441K	0.14%	218

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Investors Capital Advisory Services's TEVA Position: Q2 2016 in Review

Investors Capital Advisory Services increased its Teva Pharmaceuticals (TEVA) stake by 2.4% in Q2 2016, buying an estimated $11.3K and bringing the position to 9,224 shares worth $463K. The position accounts for 0.09% of the portfolio, ranked #299.

Investors Capital Advisory Services first reported a position in TEVA in Q2 2013 and has held it in 13 quarters since. The position peaked at $598K in Q1 2015. 813 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Investors Capital Advisory Services held 9,224 shares of Teva Pharmaceuticals worth $463K as of Q2 2016.
Investors Capital Advisory Services bought 213 Teva Pharmaceuticals shares in Q2 2016, an estimated $11.3K.
Teva Pharmaceuticals made up 0.09% of Investors Capital Advisory Services's portfolio in Q2 2016, its #299 holding.
Investors Capital Advisory Services first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 13 quarters since.
Investors Capital Advisory Services's Teva Pharmaceuticals position peaked at $598K in Q1 2015.
813 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Investors Capital Advisory Services's 13F filing for Q2 2016, filed 2 Aug 2016.